Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program.

Addington J, Liu L, Chu M, Jungert K, Penzel N, Pasternak O, Farina E, Carrion RE, Corcoran CM, Mittal VA, Strauss GP, Yung AR, Alameda L, Arango C, Borders O, Bouix S, Breitborde NJK, Broome MR, Cadenhead KS, Castillo-Passi RI, Chen EYH, Choi J, Coleman MJ, Conus P, Diaz-Caneja CM, Ellman LM, Poli PF, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Kapur T, Kelly S, Kerr MJ, Keshavan MS, Kim M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Lewandowski KE, Mamah D, Marcy PJ, Mathalon DH, Mourgues C, Nordentoft M, Nunez AR, Pearlson GD, Perez J, Perkins DO, Powers AR, Rogers J, Sabb FW, Schiffman J, Seitz-Holland J, Shah JL, Silverstein SM, Smesny S, Stone WS, Thompson JL, Upthegrove R, Verma S, Wang J, Wolf DH, Zhang T, Addamo L, Buccilli K, Dwyer D, Todd S, Cho YT, Fontenau C, Tamayo Z, Bearden CE, Kane JM, McGorry PD, Kahn RS, Shenton ME, Woods SW, Accelerating Medicines Partnership® Schizophrenia Nelson Barnaby, Calkins ME. Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program. Schizophr Bull Open. 2025 Jan; 6(1):sgaf012.